Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial.

J Prev Alzheimers Dis · 2025 · PMC12184016 · PMID 39800452

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Co-primary endpoint ADCS-ADL improved for blarcamesine-treated patients relative to placebo but did not reach statistical significance at 48 weeks.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.